Journal of Clinical Virology
Volume 44, Issue 4 , Pages 302-307 , April 2009

Quantitative multiplex PCR assay for the detection of the seven clinically most relevant high-risk HPV types

  • Martina Schmitz

      Affiliations

    • Klinik für Geburtshilfe und Frauenheilkunde, Universitätsklinikum Jena, Germany
    • ,
  • Cornelia Scheungraber

      Affiliations

    • Klinik für Geburtshilfe und Frauenheilkunde, Universitätsklinikum Jena, Germany
    • ,
  • Jörg Herrmann

      Affiliations

    • Klinik für Geburtshilfe und Frauenheilkunde, Universitätsklinikum Jena, Germany
    • ,
  • Karin Teller

      Affiliations

    • Klinik für Geburtshilfe und Frauenheilkunde, Universitätsklinikum Jena, Germany
    • ,
  • Mieczyslaw Gajda

      Affiliations

    • Institut für Pathologie, Universitätsklinikum Jena, Germany
    • ,
  • Ingo B. Runnebaum

      Affiliations

    • Klinik für Geburtshilfe und Frauenheilkunde, Universitätsklinikum Jena, Germany
    • ,
  • Matthias Dürst

      Affiliations

    • Klinik für Geburtshilfe und Frauenheilkunde, Universitätsklinikum Jena, Germany
    • Corresponding Author InformationCorresponding author at: Abteilung Frauenheilkunde, Klinik für Geburtshilfe und Frauenheilkunde, Universitätsklinikum Jena, Bachstr. 18, 07743 Jena, Germany. Tel.: +49 3641 933720; fax: +49 3641 934272.

Received 10 October 2008 ,Revised 29 December 2008 ,Accepted 14 January 2009.

References 

  1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–19
  2. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518–527
  3. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. HPV in the etiology of human cancer. Vaccine. 2006;24(Suppl. 3):S3/1–S/10[Chapter 1]
  4. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119:1095–1101
  5. Grce M, Davies P. Human papillomavirus testing for primary cervical cancer screening. Expert Rev Mol Diagn. 2008;8:599–605
  6. Wright TC, Schiffman M, Solomon D, Cox JT, Garcia F, Goldie S, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol. 2004;103:304–309
  7. van Ham MA, Bakkers JM, Harbers GK, Quint WG, Massuger LF, Melchers WJ. comparison of two commercial assays for detection of human papillomavirus (HPV) in cervical scrape specimens: validation of the Roche AMPLICOR HPV test as a means to screen for HPV genotypes associated with a higher risk of cervical disorders. J Clin Microbiol. 2005;43:2662–2667
  8. Jacobs MV, de Roda Husman AM, van den Brule AJ, Snijders PJ, Meijer CJ, Walboomers JM. Group-specific differentiation between high- and low-risk human papillomavirus genotypes by general primer-mediated PCR and two cocktails of oligonucleotide probes. J Clin Microbiol. 1995;33:901–905
  9. Manos M, Ting Y, Wright D, Lewis A, Broker T, Wolinsky S. Use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer Cells. 1989;7:209–214
  10. Castle PE, Solomon D, Schiffman M, Wheeler CM. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst. 2005;97:1066–1071
  11. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97:1072–1079
  12. Venturoli S, Ambretti S, Cricca M, Leo E, Costa S, Musiani M, et al. Correlation of high-risk human papillomavirus genotypes persistence and risk of residual or recurrent cervical disease after surgical treatment. J Med Virol. 2008;80:1434–1440
  13. Brummer O, Hollwitz B, Bohmer G, Kuhnle H, Petry KU. Human papillomavirus-type persistence patterns predict the clinical outcome of cervical intraepithelial neoplasia. Gynecol Oncol. 2006;102:517–522
  14. Kleter B, van Doorn LJ, Schrauwen L, Molijn A, Sastrowijoto S, ter Schegget J, et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol. 1999;37:2508–2517
  15. van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ, Snijders PJ. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol. 2002;40:779–787
  16. Lindh M, Gorander S, Andersson E, Horal P, Mattsby-Balzer I, Ryd W. Real-time Taqman PCR targeting 14 human papilloma virus types. J Clin Virol. 2007;40:321–324
  17. Nishiwaki M, Yamamoto T, Tone S, Murai T, Ohkawara T, Matsunami T, et al. Genotyping of human papillomaviruses by a novel one-step typing method with multiplex PCR and clinical applications. J Clin Microbiol. 2008;46:1161–1168
  18. Holland PM, Abramson RD, Watson R, Gelfand DH. Detection of specific polymerase chain reaction product by utilizing the 5′–3′ exonuclease activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci USA. 1991;88:7276–7280
  19. Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004;111:278–285
  20. Schiffman M, Khan MJ, Solomon D, Herrero R, Wacholder S, Hildesheim A, et al. A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst. 2005;97:147–150
  21. Durst M, Gissmann L, Ikenberg H, zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA. 1983;80:3812–3815
  22. Jacobs MV, Snijders PJ, van den Brule AJ, Helmerhorst TJ, Meijer CJ, Walboomers JM. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol. 1997;35:791–795
  23. Jacobs MV, Snijders PJ, Voorhorst FJ, Dillner J, Forslund O, Johansson B, et al. Reliable high risk HPV DNA testing by polymerase chain reaction: an intermethod and intramethod comparison. J Clin Pathol. 1999;52:498–503
  24. Klug SJ, Hukelmann M, Hollwitz B, Duzenli N, Schopp B, Petry KU, et al. Prevalence of human papillomavirus types in women screened by cytology in Germany. J Med Virol. 2007;79:616–625
  25. Bulkmans NW, Rozendaal L, Snijders PJ, Voorhorst FJ, Boeke AJ, Zandwijken GR, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44 102 women. Int J Cancer. 2004;110:94–101
  26. Schneider A, Hoyer H, Lotz B, Leistritza S, Kuhne-Heid R, Nindl I, et al. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int J Cancer. 2000;89:529–534
  27. Sabol I, Salakova M, Smahelova J, Pawlita M, Schmitt M, Gasperov NM, et al. Evaluation of different techniques for identification of human papillomavirus types of low prevalence. J Clin Microbiol. 2008;46:1606–1613
  28. Yoshida T, Sano T, Kanuma T, Owada N, Sakurai S, Fukuda T, et al. Quantitative real-time polymerase chain reaction analysis of the type distribution, viral load, and physical status of human papillomavirus in liquid-based cytology samples from cervical lesions. Int J Gynecol Cancer. 2008;18:121–127
  29. Fiander AN, Hart KW, Hibbitts SJ, Rieck GC, Tristram AJ, Beukenholdt RW, et al. Variation in human papillomavirus type-16 viral load within different histological grades of cervical neoplasia. J Med Virol. 2007;79:1366–1369
  30. Monnier-Benoit S, Dalstein V, Riethmuller D, Lalaoui N, Mougin C, Pretet JL. Dynamics of HPV16 DNA load reflect the natural history of cervical HPV-associated lesions. J Clin Virol. 2006;35:270–277

PII: S1386-6532(09)00038-9

doi: 10.1016/j.jcv.2009.01.006

Journal of Clinical Virology
Volume 44, Issue 4 , Pages 302-307 , April 2009

Article Tools

* Image Usage & Resolution